Bracco Diagnostics Inc.

Bracco Diagnostics Inc., a foreign-owned diagnostic imaging company headquartered in Italy with U.S. operations in Princeton, New Jersey and Monroe Township, New Jersey, supplies radiopharmaceuticals, rubidium-82 generators, cardiac imaging equipment, contrast media, and medical imaging supplies to federal healthcare agencies as a prime contractor under full-and-open competition with no set-aside designations across its entire portfolio.

Bracco operates exclusively as a prime contractor (100% of awards) on the federal market, with no subcontractor footprint in the source data. The company's concrete capability portfolio centers on rubidium-82 generators and PET systems for cardiac imaging, Cardiogen-82 radiopharmaceutical products, HeartSee cardiac imaging software, contrast media, and nuclear medicine equipment maintenance. Representative recent work includes a $2.8 million delivery order from Department of Veterans Affairs Veterans Integrated Service Network 1 for Cardiogen radiopharmaceutical rubidium generators (awarded October 2025, completion October 2026); a $2.32 million purchase order from the Defense Health Agency for Cardiogen-82 generators and HeartSee software (awarded October 2025, completion September 2030); a $1.77 million purchase order from VISN 17 for PET rubidium-82 generators and related supplies (awarded September 2023, completion September 2028); and a $1.095 million definitive contract from VISN 22 for rubidium RB-82 generator equipment and accessories (awarded July 2024, completion July 2027).

Customer concentration is heavily skewed toward the Department of Veterans Affairs. The top five customers by potential value account for 79% of combined potential value across all awards, led by VA VISN 12 (37 awards, $134.9 million), VISN 8 (22 awards, $10.5 million), VISN 17 (54 awards, $8.7 million), VISN 1 (19 awards, $7.9 million), and VISN 23 (24 awards, $6 million). The Defense Health Agency and Department of the Navy Bureau of Medicine and Surgery represent secondary customer bases. By award count, VISN 17 leads with 54 awards, but the count-versus-value split reveals VISN 12's disproportionate dollar concentration ($134.9 million on 37 awards). Across the portfolio, 26 distinct customer agencies are served, though VA healthcare entities dominate.

Bracco holds a single-award indefinite delivery contract with VISN 17 valued at $1,735,819.44 through March 11, 2028 for PET rubidium RB-82 systems, which serves as the parent vehicle for multiple delivery orders issued across fiscal years 2024 through 2026. The company also maintains a position on the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), which anchors the majority of task order activity. The top parent vehicles by task order count are the Federal Supply Schedule V797P5864X (2,061 task orders, $7.2 million combined potential value) and the Pharmaceuticals and Drugs Federal Supply Schedule (83 task orders, $30.5 million combined potential value). The source data reflects PSC concentration across Medical and Surgical Instruments, Equipment, and Supplies (1,260 awards), Drugs and Biologicals (948 awards), and Imaging Equipment and Supplies (590 awards), aligned with NAICS 325412 (Pharmaceutical Preparation Manufacturing, 2,309 awards).

Award activity averaged eight awards per year from 2023 to 2024 and grew to ten awards in 2025, though the source reflects only two awards to date in 2026. Nine awards with combined potential value of $6.8 million face ultimate completion within the next twenty-four months, representing recompete exposure. Across the portfolio, $43.6 million has been obligated against $212.2 million in combined potential value (21% obligation rate), indicating substantial unexercised capacity on active vehicles. The company competes on full-and-open basis without minority or small business set-aside designation; all named awards carry "No Set-Aside Used" designations across both GSA Schedule and VA IDIQ work.